Mason Capital Acquires Forward Pharma A/S via Tender Offer

CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd

December 14, 2021

Pharmaceuticals

CSL Limited has launched an all-cash tender offer to acquire all publicly held shares of Vifor Pharma Ltd for US$179.25 per share, implying an aggregate equity value of approximately US$11.7 billion. The transaction, unanimously recommended by both boards, expands CSL's presence in nephrology, iron deficiency and cardio-renal therapies and will be funded through a combination of equity placement, new debt and existing cash facilities.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Danforth Advisors Acquires PharmaDirections

August 25, 2025

Healthcare Services

Danforth Advisors, a PE-backed life sciences advisory platform, has acquired PharmaDirections, a virtual drug development partner. The acquisition adds more than 150 specialists and expands Danforth's integrated capabilities across discovery, non-clinical and clinical development, CMC, regulatory strategy, and program and alliance management.

Jazz Pharmaceuticals Acquires GW Pharmaceuticals for $7.2 billion

February 3, 2021

Pharmaceuticals

Jazz Pharmaceuticals plc has entered into a definitive agreement to acquire GW Pharmaceuticals plc for $220 per ADS (comprised of $200 cash and $20 in Jazz ordinary shares), implying total consideration of approximately $7.2 billion ($6.7 billion net of GW cash). The boards of both companies approved the transaction, which is expected to close in Q2 2021 subject to GW shareholder approval, court sanction and customary regulatory clearances; the combined company will strengthen Jazz's neuroscience portfolio and global commercial footprint.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.

Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals

October 11, 2021

Pharmaceuticals

Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals in a cash tender offer valued at approximately $400 million upfront plus up to $50 million in contingent value rights, for total consideration of about $450 million. The acquisition gives Supernus two marketed CNS products (GOCOVRI and Osmolex ER), diversifies its Parkinson’s disease portfolio and is expected to be accretive with material synergies in 2022.